Atossa Genetics (ATOS) Earning Somewhat Favorable Media Coverage, Analysis Shows

Press coverage about Atossa Genetics (NASDAQ:ATOS) has trended somewhat positive on Thursday, according to Accern. The research group identifies positive and negative news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Atossa Genetics earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 47.3062540368821 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

These are some of the news headlines that may have effected Accern Sentiment Analysis’s scoring:

A number of analysts have recently issued reports on the stock. Noble Financial set a $10.00 price objective on shares of Atossa Genetics and gave the company a “buy” rating in a research note on Tuesday, May 15th. Maxim Group set a $10.00 price objective on shares of Atossa Genetics and gave the company a “buy” rating in a research note on Monday, May 14th. Finally, ValuEngine upgraded shares of Atossa Genetics from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd.

Shares of ATOS traded down $0.09 during mid-day trading on Thursday, reaching $2.51. 161,048 shares of the stock traded hands, compared to its average volume of 393,422. Atossa Genetics has a 12-month low of $2.51 and a 12-month high of $19.08.

Atossa Genetics (NASDAQ:ATOS) last posted its quarterly earnings data on Monday, May 14th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.15. equities research analysts predict that Atossa Genetics will post -3.69 EPS for the current fiscal year.

About Atossa Genetics

Atossa Genetics Inc a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase 2 clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen, as well as treatment for breast density and other breast health conditions.

Insider Buying and Selling by Quarter for Atossa Genetics (NASDAQ:ATOS)

Receive News & Ratings for Atossa Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit